Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of consolidation immunotherapy after platinum chemoradiotherapy with IMRT or brachytherapy in unresectable stage III non-small cell lung cancer
ChiCTR2300076399Phase 3Not yet recruiting
- Sponsor
- Affiliated Hospital of Southwest Medical University
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Affiliated Hospital of Southwest Medical University. Primary endpoints: progression-free survival and safety. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
cisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300076399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076399.